Format

Send to

Choose Destination
Oncotarget. 2017 Aug 21;8(42):73050-73062. doi: 10.18632/oncotarget.20377. eCollection 2017 Sep 22.

Efficacy and safety of immunosuppressive medications for steroid-resistant nephrotic syndrome in children: a systematic review and network meta-analysis.

Li S1,2, Yang H3,4, Guo P1,2, Ao X1,5, Wan J3,5, Li Q1,3,2, Tan L1,5.

Author information

1
Department of Emergency, Children's Hospital of Chongqing Medical University, Chongqing, China.
2
Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China.
3
Department of Nephrology, Children's Hospital of Chongqing Medical University, Chongqing, China.
4
Chongqing International Science and Technology Cooperation Center for Child Development and Disorders, Chongqing, China.
5
Key Laboratory of Pediatrics in Chongqing, Chongqing, China.

Abstract

BACKGROUND:

Conventional meta-analyses and randomized controlled trials have shown inconsistent results regarding the efficacy of immunosuppressants for pediatric steroid-resistant nephrotic syndrome (SRNS).

OBJECTIVE:

To conduct a network meta-analysis aimed at evaluating the efficacy and safety of available immunosuppressive agents in pediatric patients with SRNS.

STUDY METHODS:

MEDLINE, the Cochrane Central Register of Controlled Trials, and EMBASE were searched on January 2017. Data from randomized controlled trials (RCTs) were included. The main outcomes analyzed were efficacy [number/portion with complete remission (CR), number/portion with partial remission (PR), and total number/portion in remission (TR)] and safety [adverse secondary event (ASE) rates].

RESULTS:

A meta-analysis of 18 RCTs showed that tacrolimus was more efficacious for achieving CR than intravenous (i.v.) cyclophosphamide, mycophenolate mofetil (MMF), oral cyclophosphamide, leflunomide, chlorambucil, azathioprine, and plaebo/nontreatment (P/NT), and more efficacious than i.v. cyclophosphamide, oral cyclophosphamide, and P/NT in terms of TR outcomes. Cyclosporin was associated with a greater CR rate than i.v. cyclophosphamide, MMF, oral cyclophosphamide, chlorambucil, azathioprine, or P/NT, and associated with a greater TR rate than i.v. cyclophosphamide, oral cyclophosphamide, or P/NT. MMF was found to be more efficacious than i.v. cyclophosphamide and oral cyclophosphamide in terms of TR.

CONCLUSIONS:

Tacrolimus and cyclosporine may be preferred initial treatments for children with SRNS. MMF may be another option for this patient population. Further studies of the efficacy and safety of these three drugs in children with SRNS should be pursued.

KEYWORDS:

SRNS; immunosuppressant; multiple-treatments meta-analysis; pediatrics

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no conflicts of interest concerning this article.

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center